The Problem Nobody's Solving at the Right Scale
Here's an uncomfortable fact: we have roughly as many effective pharmacotherapies for nicotine use disorder today as we did two decades ago. Varenicline, bupropion, nicotine replacement — they help some people, sometimes. Roughly one in four actually stays quit at six months on the best available regimen. The rest cycle through relapse, guilt, another attempt. Meanwhile, the nicotine landscape is morphing faster than our treatment toolkit can keep pace. FDA/CDC National Youth Tobacco Survey data shows oral nicotine pouch use among American youth nearly quadrupled between 2022 and 2025. That's not a stable public-health picture. That's an escalation.
Against this backdrop, a five-year, $943,000 K01 grant from the National Institute on Drug Abuse just landed on the bench of Dr. Cali Calarco at the University of Central Florida's Burnett School of Biomedical Sciences. Her question isn't "how does nicotine reach the brain" — we've known that for decades. It's more specific and, frankly, more promising: what happens inside individual neurons in the nucleus accumbens when nicotine forces them to reorganize their internal machinery?
The Nucleus Accumbens Is Not Just a Dopamine Faucet
Pop neuroscience describes the nucleus accumbens as the brain's "pleasure center." That's reductive to the point of being misleading. Calarco calls it something better: "a little computer that integrates a lot of signals that come in relationship to reward learning from a lot of other parts of the brain to guide behavioral choices."
The distinction matters. A faucet just pours dopamine on cue. A computer takes inputs from across the cortex, weighs them against past experience, and outputs a decision about whether you reach for something. The nucleus accumbens sits at the convergence of reinforcement learning, incentive salience, and the actual moment you choose to act. It's where wanting becomes doing.
And it's not homogeneous. Calarco's lab investigates distinct subpopulations of neurons within the accumbens, because these cells don't all respond to nicotine the same way. Some encode the reward signal itself. Others gate it, suppress it, or flag it as no longer novel. Understanding which subpopulation gets hijacked — and how — is the research's first-order concern.
Mitochondria Were Never Just Power Plants
The old biology textbook had mitochondria as the cell's battery pack. Generate ATP, done. That picture was always incomplete, but in neuroscience it was actively harmful, because it made mitochondria look like infrastructure rather than signaling hubs. They are both.
"Mitochondria have been underappreciated in neurons previously," Calarco said. "Neurons are incredibly complex cells that do incredibly complex tasks, both electrically and chemically that require a ton of energy, so we knew they were really important. But mitochondria also influence how neurons communicate with each other. They're super important for gene transcription and translation and for steroid hormone production."
Read that again. The same organelle that fuels a neuron's electrical firing also helps decide which genes get expressed and what steroid hormones get synthesized locally. In the nucleus accumbens, where synaptic plasticity is the literal substrate of addiction, that means mitochondria aren't passive passengers. They're active participants in the remodeling that turns casual use into compulsive seeking.
What Nicotine Actually Does to Neuronal Mitochondria
Calarco's current models track how nicotine modifies mitochondrial morphology, trafficking, and metabolic signaling in real time. Those three terms carry weight. Morphology, whether mitochondria are fused into long networks or fragmented into isolated dots, affects how well a neuron can distribute energy to its dendrites and synapses. Trafficking, whether mitochondria get delivered to the right stretch of axon at the right moment, determines whether a synapse can sustain repeated firing or fatigues. Metabolic signaling, the metabolites mitochondria release into the cytoplasm, feeds back into transcription factors that alter gene expression over hours and days.
Each of these is a potential point of therapeutic intervention. Each is also a potential failure mode: damage a mitochondrial network in the accumbens, and you might get a neuron that can't "unlearn" a drug association because it literally lacks the metabolic flexibility to remodel its synapses.
From Cocaine to Nicotine: A Lineage of Questions
This isn't Calarco's first pass at mitochondria and addiction. Her postdoctoral work at the University of Maryland, Baltimore examined mitochondrial alterations underlying cocaine-seeking behavior. The conceptual bridge is clear: cocaine and nicotine both drive compulsive drug-seeking through nucleus accumbens circuitry, and both appear to achieve this partly by reshaping mitochondrial biology in that circuitry. What shifts between the two compounds is the receptor pharmacology upstream, nicotine hits nicotinic acetylcholine receptors, cocaine blocks dopamine reuptake. The downstream organelle dysfunction looks convergent in ways that might be therapeutically useful.
The Treatment Gap This Research Targets
"There aren't that many substance use disorder treatments, and the ones available only work for a subset of people," Calarco noted. "There is room for improvement in nicotine use disorder therapies, and new pathway targets may provide more effective treatments with fewer side effects."
That last clause, fewer side effects, deserves emphasis. Most existing pharmacotherapies for nicotine addiction hit receptor systems globally. You flood the whole brain with partial agonism or you block reuptake everywhere. The reason those drugs feel like a sledgehammer to some patients is that they are sledgehammers. Mitochondrial pathways, by contrast, might offer tissue-specific or even subpopulation-specific intervention points. If you can correct the metabolic signature of a nucleus accumbens neuron that's been locked into drug-seeking, you might restore behavioral flexibility without blunting the entire reward system.
That's the optimistic version. Whether it translates from cell models to human trials is genuinely unknown, and Calarco's own framing is appropriately cautious about that distance. But the conserved nature of reward-learning circuitry means findings here could ripple outward. The same mitochondrial mechanisms she's mapping in the accumbens likely contribute to other substance use disorders and possibly compulsive behavioral dependencies.
Why This Matters Beyond the Lab
The 2020 NIDA survey found approximately 23.6 million Americans aged 12 and older with nicotine dependence in the preceding thirty days. That number predates the pouch explosion documented by the Youth Tobacco Survey. We are looking at a population whose dependency profile is shifting, younger, more diverse in delivery mechanism, increasingly using products their parents' generation never encountered, while our therapeutic options remain anchored to pharmacology designed for cigarettes.
Mitochondrial biology won't fix this overnight. It's basic research with a five-year funding horizon, building toward clinical relevance. But "basic" doesn't mean "useless." The treatments we take for granted in neurology, L-DOPA for Parkinson's, SSRIs for depression, all emerged from someone first figuring out what was actually happening at the molecular level in a specific brain region. Calarco's work is that first figuring step. Whether it produces a drug someday depends on factors beyond her bench. But the alternative, continuing to treat a subcellular pathology with systemic sledgehammers, is a strategy we can already see isn't working well enough.
